Clinical trial
Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump…
NCT00161200 · University of Medicine and Dentistry of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00161200 |
|---|---|
| Title | Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor |
| Official title | Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Esophageal Metaplasia |
| Intervention type | Drug |
| Interventions | Ranitidine & Pantoprazole |
| Enrollment | 60 |
| Start date | Dec 1, 2002 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 11, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: